The Phase III clinical trial for Formycon’s biosimilar ustekinumab candidate FYB202 shows comparable efficacy to the reference product Stelara® which is used to treat various severe inflammatory conditions such as moderate to severe psoriasis. “The positive interim phase III study results mark an important milestone and underline our expertise in the development of high-quality biosimilars”, emphasizes Formycon CEO Dr. Stefan Glombitza.
Read more in our Corporate News.
